Drug Manufacturers - General
🏛 Recent congressional trades
“Amgen pulled back 1.6% Friday as the UK's MHRA suspended Tavneos for new patients effective September 1, adding to existing FDA withdrawal proposals. This regulatory overhang pressured the stock despite an otherwise strong trajectory -- AMGN is up 8% in a month, 25% in three months, and trades 10% above its 50-day MA near 52-week highs. Tavneos is a small revenue contributor (~1%), but the regulatory optics are incrementally negative near-term. For long-term holders, the broader pipeline and established portfolio remain intact; this pullback looks like a buying opportunity within a strong uptrend.”
Updated 09-07 05:43
Loading…
The Federal Reserve held rates at 3.50%-3.75% in July 2026 after three cuts in 2025, keeping borrowing costs supportive for capital-intensive biotech R&D; lower rates historically lift long-duration biotech valuations and improve M&A financing conditions.
The BIOSECURE Act (enacted December 2025) and the newly introduced Biotech Investment National Security Act (BINSA, June 2026) heighten US-China biotech decoupling risks, and Amgen's own 10-Q flags geopolitical tensions and trade policy as material risk factors to its supply chain and operations.
Amgen's MariTide is advancing in a broad Phase 3 program as a differentiated monthly obesity injectable targeting the $92 billion obesity market in 2026, while Tezspire posted positive Phase 3 data in eosinophilic esophagitis — reinforcing a strong pipeline narrative.
AMGN has surged 36% YTD and 60% over 12 months, massively outperforming the S&P 500, but at $437 it trades above the $390 consensus analyst target; technical indicators (MACD negative, RSI exiting overbought) suggest near-term consolidation risk near the 52-week high of $447.
UK MHRA suspended Tavneos for new patients from September 1, 2026, citing unreliable pivotal trial data, following the European Commission's August revocation and the FDA's proposed US withdrawal — the stock dropped 6.8% on September 4, wiping out recent gains.
Updated 09-07 05:43
Updated 09-07 05:43
Loading…